Segmed Inc., a leader in real-world imaging data for research and AI development, has appointed David Gascoigne as Chief Executive Officer (CEO). This leadership position marks a pivotal moment as the company accelerates its next phase of growth and innovation.

Dr. Martin Willemink, M.D., Ph.D., the company’s Co-founder and former CEO, will assume the role of Chief Scientific Officer to focus on advancing the company’s scientific vision, academic collaborations, and market presence to support the company’s next phase of growth.

About David Gascoigne

Gascoigne brings more than 30 years of experience driving innovation and growth at the intersection of healthcare, life sciences, AI, and real-world data. A serial entrepreneur and proven operator, he has built and scaled businesses ranging from early-stage start-ups to global enterprises.

Most recently, Gascoigne served as CEO of Almaden Genomics, where he led the launch and commercialization of a cloud based, no-code genomics platform spun out of IBM Research. The software was the first no-code platform to accelerate genomic data analysis for researchers, bioinformaticians, and life science companies. His prior executive roles include leadership positions at IQVIA where he was GM of Commercial Analytics, Symphony Health where he was EVP of Consulting, Analytics and Innovation, Sutherland Global Services where he was SVP of Healthcare Analytics, as well as serving as Chief Operating Officer at GNS Healthcare and a Partner in Digital Analytics at Accenture.

Gascoigne holds an advanced degree in Applied Statistics from the University of Sheffield in the U.K.

“I’m honored to join Segmed at such a pivotal time,” said Gascoigne. “The company has built a remarkable foundation, and I look forward to working with Martin and the entire team to expand our reach, partnerships, and innovation in healthcare data.”